Combination treatment is typically more effective than treatment with methotrexate alone, but some patients may experience adverse events with methotrexate that make monotherapy desirable.
A new study published in Arthritis & Rheumatology found that patients with rheumatoid arthritis (RA) treated with tocilizumab (Actemra, developed by Roche) plus methotrexate who have achieved low disease activity can discontinue methotrexate without significant worsening of disease activity.1 Combination treatment is typically more effective than treatment with methotrexate alone, but some patients may experience adverse events with methotrexate that make monotherapy desirable.
Tocilizumab is an interleukin-6 inhibitor indicated to treat patients with moderate to severe RA who have had an inadequate response to 1 or more disease-modifying anti-rheumatic drugs. Additionally, tocilizumab is also indicated to treat giant cell arteritis in adult patients, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.
Read more about interleukin-6 inhibitors.
This study, COMP-ACT, a randomized, multicenter, double-blind, parallel group trial, compared tocilizumab plus methotrexate with tocilizumab monotherapy in adult patients with RA who had previous inadequate responses to methotrexate. At baseline, all patients began treatment with subcutaneous tocilizumab, either weekly or every 2 weeks, and continued to receive a pre-baseline dose of oral methotrexate.
At 24 weeks, patients who reached disease activity score in a count of 28 joints with erythrocyte sedimentation rate (DAS28-ESR) of 3.2 or lower were then randomized to either discontinue methotrexate and continue tocilizumab as a monotherapy or stay on tocilizumab plus methotrexate until week 52.
Researchers found that patients who received tocilizumab plus methotrexate who had achieved low disease activity were able to discontinue methotrexate without significant worsening of disease activity in the following 16 weeks.
For patients who prefer monotherapy, these results will likely be welcome news. They may also be welcome news for Roche, for whom Actemra has been fairly lucrative, earning the company around $1.9 million last year.
Because the biologic is still covered by patents, there has been relatively little development of tocilizumab biosimilars. However last month, Bio-Thera, a Chinese-based biotechnology company, announced that it has initiated a phase 1 clinical trial for its proposed tocilizumab biosimilar, BAT1806.
Reference
Kremer J, Rigby W, Singer N, et al. Sustained response following discontinuation of methotrexate in patients with rheumatoid arthritis treated with subcutaneous tocilizumab [published online March 25, 2018]. doi.org/10.1002/art.40493.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.